Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

Hong Kong · Delayed Price · Currency is HKD

469.20

+2.60 (0.56%)

At close: Apr 28, 2026

59.70% (1Y)

Market Cap	113.26B
Revenue (ttm)	2.29B
Net Income (ttm)	-425.06M
Shares Out	241.40M
EPS (ttm)	-1.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	238,006
Average Volume	595,807
Open	461.80
Previous Close	466.60
Day's Range	454.20 - 478.80
52-Week Range	280.00 - 581.00
Beta	0.02
RSI	49.75
Earnings Date	May 18, 2026

About HKG:6990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Employees 2,045

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 6990

Full Company Profile

Financial Performance

In 2025, HKG:6990's revenue was 2.06 billion, an increase of 6.46% compared to the previous year's 1.93 billion. Losses were -381.97 million, 43.2% more than in 2024.

Financial numbers in CNY Financial Statements

News

Sichuan Kelun-Biotech Biopharmaceutical Earnings Call Transcript: H2 2025

Revenue grew 6.5% to CNY 2.06 billion in 2025, driven by expanded commercialization and NRDL inclusion. Gross margin rose 16.1%, but net loss increased due to higher sales and R&D expenses. Strong cash reserves and global partnerships position the company for further growth.

5 weeks ago - Transcripts

Sichuan Kelun-Biotech Biopharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference

A leading biopharma presented its robust pipeline, including four approved oncology products and innovative ADCs, with strong clinical results and global partnerships. Strategic priorities include expanding indications, advancing novel drug conjugates, and growing international presence.

3 months ago - Transcripts

Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up

(RTTNews) - Crescent Biopharma, Inc. (CBIO), on Thursday announced an exclusive partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize oncology therapeutics, i...

5 months ago - Nasdaq

Sichuan Kelun-Biotech Biopharmaceutical Earnings Call Transcript: H1 2025

First-half 2025 revenue reached ¥950 million, driven by strong commercialization and R&D partnerships, with lung cancer as the top sales contributor. The company maintains a ¥1 billion sales target for the year, supported by robust cash reserves and ongoing expansion of its ADC and bi-specific pipeline.

9 months ago - Transcripts